Every round on record, with the sources behind each and the investors on them.
6 sources · checked 33 times, last 4d ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The €4.3 million financing mentioned by sources was completed in spring 2025 and is prior funding, not part of this round.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Funding round | $3.3M €2.9 million | 2026-10-01 | not stated | No recent discussion |
6 sources · checked 33 times, last 4d ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 4 of 6 sources The €4.3 million financing mentioned by sources was completed in spring 2025 and is prior funding, not part of this round. | ||||
Omnio develops a recombinant plasminogen biologic intended to restart the body's healing process for hard-to-heal chronic wounds, especially diabetic foot ulcers.
Omnio is targeting hard-to-heal diabetic foot ulcers, which its pages describe as a major source of suffering, mobility loss and amputation risk, with advanced cases costing healthcare systems an estimated €50,000 per wound episode. Its recombinant plasminogen is intended to address the biology of stalled healing and infection rather than merely manage symptoms, and the latest €2.9 million round is funding GMP manufacturing and toxicology work ahead of planned Phase I/IIa patient studies.
Checked against 10 sources on Oct 3
None named.
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Capital injection | approximately 4.3 million euros (about SEK47 million) | 2025-05 | not stated | |
| New share issue | 5.5MSEK | 2021-12-06 | not stated | |